MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.

MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.
复制标题

MicroRNA-424 通过下调卵巢透明细胞癌中的双皮质素样激酶 1 来抑制细胞迁移、侵袭和上皮间质转化。

DOI:
10.1016/j.biocel.2017.01.020
复制
发表时间:
2017-04
影响因子:
4
通讯作者:
武欣
武欣
中科院分区:
生物学2区
文献类型:
--
作者:
武欣

文献摘要

参考文献

相似文献

双重皮质醇样激酶1(DCLK1)在许多肿瘤中高表达,是一种肿瘤干细胞标记物。在这里,我们研究了DCLK1和microRNA-424(miR-424)在卵巢透明细胞癌(OCCC)中的作用。卵巢透明细胞癌是卵巢上皮癌的一种组织病理学亚型,与预后不良和化疗耐药有关。对30例OCCC患者标本的分析表明,与癌旁组织相比,肿瘤组织中DCLK1表达上调,miR-424表达下调。DCLK1过表达促进OCCC细胞的增殖、迁移和侵袭,而DCLK1基因敲除降低了细胞的存活率和侵袭力,并在体内诱导生长。双荧光素酶分析显示miR-424直接靶向DCLK1并下调其表达。用miR-424基因转染ES-2细胞可模拟DCLK1的下调,并抑制DCLK1过表达上调基质金属蛋白酶-9和促进上皮-间充质转化(EMT)的作用。综上所述,这些数据表明miR-424有能力通过下调DCLK1来抑制OCCC的细胞侵袭和EMT,为该疾病的治疗提供了潜在的治疗靶点和策略。
Doublecortin-like kinase 1 (DCLK1) is overexpressed in many cancers and acts as a tumor stem cell marker. Here, we investigated the role of DCLK1 and microRNA-424 (miR-424) in ovarian clear cell carcinoma (OCCC), a histopathologically distinct subtype of epithelial ovarian cancer associated with poor prognosis and chemotherapy resistance. Analysis of samples from 30 OCCC patients showed that DCLK1 was upregulated and miR-424 was downregulated in tumors compared with adjacent non-tumor tissues. DCLK1 overexpression promoted OCCC cell proliferation, migration, and invasion, whereas DCLK1 knockdown reduced cell viability and invasion and induced growth arrestin vitroandin vivo. Dual-luciferase reporter assays revealed that miR-424 directly targets DCLK1 and downregulates its expression. Transfection of ES-2 cells with miR-424 mimics downregulated DCLK1 and suppressed the effects of DCLK1 overexpression on upregulating matrix metalloprotease-9 and promoting epithelial-mesenchymal transition (EMT). Taken together, these data demonstrate that miR-424 has the capacity to suppress cell invasion and EMT in OCCC by downregulating DCLK1, suggesting potential therapeutic targets and strategies for the treatment of this disease.
DOI: 10.1186/s13048-016-0251-x
发表时间: 2016-07-04
影响因子: 4
作者:
Ma FH;Qiang JW;Zhang GF;Li HM;Cai SQ;Rao YM
通讯作者: Rao YM
DOI: 10.18632/oncotarget.2393
发表时间: 2014-10-15
期刊: Oncotarget
影响因子: --
作者:
Chandrakesan P;Weygant N;May R;Qu D;Chinthalapally HR;Sureban SM;Ali N;Lightfoot SA;Umar S;Houchen CW
通讯作者: Houchen CW
DOI: 10.1186/1476-4598-13-103
发表时间: 2014-05-06
期刊: Molecular cancer
影响因子: 37.3
作者:
Weygant N;Qu D;Berry WL;May R;Chandrakesan P;Owen DB;Sureban SM;Ali N;Janknecht R;Houchen CW
通讯作者: Houchen CW
DOI: 10.1186/1477-3155-9-40
发表时间: 2011-09-19
影响因子: 10.2
作者:
Sureban SM;May R;Mondalek FG;Qu D;Ponnurangam S;Pantazis P;Anant S;Ramanujam RP;Houchen CW
通讯作者: Houchen CW
DOI: 10.1053/j.gastro.2009.05.004
发表时间: 2009-08
期刊: Gastroenterology
影响因子: 29.4
作者:
Sureban SM;May R;Ramalingam S;Subramaniam D;Natarajan G;Anant S;Houchen CW
通讯作者: Houchen CW